Biogen Stock Quote 1BIIB - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

136.85

Bid

136.60

Ask

138.50

Volume

135.75 Day's Range 136.85

133.30 52 Week Range 229.20

Market Cap

19.942B

Previous Close

141.35

Open

135.75

Last Trade

136.85

Last Trade Time

05:06:03

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

145,719,340

Dividend Yield

PE Ratio

17.87

Earnings Per Share (EPS)

7.97

Revenue

9.84B

Net Profit

1.16B

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.biogen.com

Headquarters

Wilmington, Delaware, USA

Founded

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Italian Stock Exchange with ticker 1BIIB. The last closing price for Biogen was 141.35 €. Over the last year, Biogen shares have traded in a share price range of 133.30 € to 229.20 €.

Biogen currently has 145,719,340 shares outstanding. The market capitalization of Biogen is 20.60 € billion. Biogen has a price to earnings ratio (PE ratio) of 17.87.

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance dosing may be easier for patients and care partners to...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease LEQEMBI is the only FDA-approved anti-amyloid...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases The collaboration aims to...

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-4.35	-3.08073654391	141.2	141.35	135.75	31	139.46176471	DE
4	-7.4	-5.12998266898	144.25	145.4	133.3	47	137.83542413	DE
12	-21.9	-13.7952755906	158.75	160.3	133.3	54	145.0556134	DE
26	-48.4	-26.1268556005	185.25	189.25	133.3	50	156.1284116	DE
52	-87.35	-38.960749331	224.2	229.2	133.3	42	174.05280358	DE
156	-78.75	-36.525974026	215.6	244.6	133.3	39	176.8980405	DE
260	-78.75	-36.525974026	215.6	244.6	133.3	39	176.8980405	DE

1BIIB - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is 136.85 €

How many Biogen shares are in issue?

Biogen has 145,719,340 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is EUR 20.6B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of 133.30 € to 229.20 € during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 17.87

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2.11

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9.84B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1.16B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WRKT25Roket Sharing Company Spa	0.0009 € (28.57%)	1.9k
IVGIveco Group NV	13.60 € (17.19%)	12.46M
ARTDeodatoGallery SpA	0.338 € (11.92%)	153k
1PMPhillip Morris International Inc	139.72 € (11.26%)	23
WART28DeodatoGallery SpA	0.0499 € (10.89%)	2.1k
SOGESASoges Group AA	0.0008 € (-83.33%)	36.9k
1NKLANikola Corp	0.55 € (-28.57%)	23.76k
WRDF25Redelfi SpA	1.29 € (-14.47%)	5k
NTWNetweek SpA	0.108 € (-11.48%)	1.73M
FDAFidia	0.0112 € (-9.68%)	7M
TITTelecom Italia SpA	0.2943 € (4.36%)	485.92M
BPEBper Banca SPA	6.29 € (-8.73%)	55.83M
TITRTelecom Italia	0.3349 € (3.52%)	49.6M
ISPIntesa Sanpaolo Spa	4.3275 € (-0.49%)	34.63M
BMPSBanca Monte Dei Paschi Di Siena Spa	6.404 € (0.16%)	14.25M